News & Updates
Filter by Specialty:
Resistance exercise prevents ADT-induced muscle loss in patients with prostate cancer
Resistance exercise training counters the negative effects of androgen deprivation therapy (ADT) and improves muscle fibre size, as well as capillarization, in patients with prostate cancer, reports a study.
Resistance exercise prevents ADT-induced muscle loss in patients with prostate cancer
09 Oct 2023
Liraglutide vs semaglutide: Which is a better GLP-1 RA for diabetic veterans?
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) liraglutide and semaglutide are both effective at lowering haemoglobin A1c (A1c) among veterans with type 2 diabetes mellitus (T2DM), reports a recent study, which provides insights into key considerations for this population.
Liraglutide vs semaglutide: Which is a better GLP-1 RA for diabetic veterans?
06 Oct 2023
Early use of DPP-4 inhibitors delays insulin initiation in Chinese T2D patients
Early dipeptidyl peptidase 4 (DPP-4) inhibitor intensification delays insulin initiation in Chinese patients with type 2 diabetes (T2D), a cohort study in Hong Kong has shown.
Early use of DPP-4 inhibitors delays insulin initiation in Chinese T2D patients
06 Oct 2023
Icodec with app superior to OD analogues in insulin-naive T2D
Once-weekly insulin icodec with a dosing guide app is better than once-daily (OD) basal insulin analogues at reducing glycated haemoglobin (HbA1c) and improving treatment satisfaction and compliance in patients with type 2 diabetes (T2D), a study has shown. In addition, hypoglycaemia rates were low and similar between treatment groups.
Icodec with app superior to OD analogues in insulin-naive T2D
05 Oct 2023
Semaglutide scores again, this time for HFpEF in obese
Once weekly injection of semaglutide causes weight loss in obese patients with heart failure with preserved ejection fraction (HFpEF), with positive shifts in symptoms and improvements in physical limitations in the STEP-HFpEF trial presented at ESC 2023.